Literature DB >> 17383950

Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading.

M W Hamrick1, X Shi, W Zhang, C Pennington, H Thakore, M Haque, B Kang, C M Isales, S Fulzele, K H Wenger.   

Abstract

Myostatin (GDF8) is a negative regulator of skeletal muscle growth and mice lacking myostatin show a significant increase in muscle mass and bone density compared to normal mice. In order to further define the role of myostatin in regulating bone mass we sought to determine if loss of myostatin function significantly altered the potential for osteogenic differentiation in bone marrow-derived mesenchymal stem cells in vitro and in vivo. We first examined expression of the myostatin receptor, the type IIB activin receptor (AcvrIIB), in bone marrow-derived mesenchymal stem cells (BMSCs) isolated from mouse long bones. This receptor was found to be expressed at high levels in BMSCs, and we were also able to detect AcvrIIB protein in BMSCs in situ using immunofluorescence. BMSCs isolated from myostatin-deficient mice showed increased osteogenic differentiation compared to wild-type mice; however, treatment of BMSCs from myostatin-deficient mice with recombinant myostatin did not attenuate the osteogenic differentiation of these cells. Loading of BMSCs in vitro increased the expression of osteogenic factors such as BMP-2 and IGF-1, but treatment of BMSCs with recombinant myostatin was found to decrease the expression of these factors. We investigated the effects of myostatin loss-of-function on the differentiation of BMSCs in vivo using hindlimb unloading (7-day tail suspension). Unloading caused a greater increase in marrow adipocyte number, and a greater decrease in osteoblast number, in myostatin-deficient mice than in normal mice. These data suggest that the increased osteogenic differentiation of BMSCs from mice lacking myostatin is load-dependent, and that myostatin may alter the mechanosensitivity of BMSCs by suppressing the expression of osteogenic factors during mechanical stimulation. Furthermore, although myostatin deficiency increases muscle mass and bone strength, it does not prevent muscle and bone catabolism with unloading.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383950      PMCID: PMC2001954          DOI: 10.1016/j.bone.2007.02.012

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  46 in total

1.  Modulation of myostatin expression during modified muscle use.

Authors:  M Wehling; B Cai; J G Tidball
Journal:  FASEB J       Date:  2000-01       Impact factor: 5.191

2.  Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin.

Authors:  Mark W Hamrick; Ke-Hong Ding; Catherine Pennington; Yuh J Chao; Yii-Der Wu; Boyd Howard; David Immel; Cesario Borlongan; Paul L McNeil; Wendy B Bollag; Walton W Curl; Jack Yu; Carlos M Isales
Journal:  Bone       Date:  2006-06-05       Impact factor: 4.398

3.  Fluid pressure gradients, arising from oscillations in intramedullary pressure, is correlated with the formation of bone and inhibition of intracortical porosity.

Authors:  Yi Xian Qin; Tamara Kaplan; Anita Saldanha; Clinton Rubin
Journal:  J Biomech       Date:  2003-10       Impact factor: 2.712

4.  Influence of muscle strength on bone strength during childhood and adolescence.

Authors:  E Schönau; E Werhahn; U Schiedermaier; E Mokow; H Schiessl; K Scheidhauer; D Michalk
Journal:  Horm Res       Date:  1996

5.  Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting.

Authors:  K E Yarasheski; S Bhasin; I Sinha-Hikim; J Pak-Loduca; N F Gonzalez-Cadavid
Journal:  J Nutr Health Aging       Date:  2002       Impact factor: 4.075

6.  Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight.

Authors:  R Lalani; S Bhasin; F Byhower; R Tarnuzzer; M Grant; R Shen; S Asa; S Ezzat; N F Gonzalez-Cadavid
Journal:  J Endocrinol       Date:  2000-12       Impact factor: 4.286

7.  Decreased bone density in ambulatory patients with duchenne muscular dystrophy.

Authors:  Luis F Aparicio; Marguerite Jurkovic; James DeLullo
Journal:  J Pediatr Orthop       Date:  2002 Mar-Apr       Impact factor: 2.324

8.  Relationship between limb and muscle blood flow in man.

Authors:  M Raitakari; P Nuutila; U Ruotsalainen; M Teräs; E Eronen; H Laine; O T Raitakari; H Iida; M J Knuuti; H Yki-Järvinen
Journal:  J Physiol       Date:  1996-10-15       Impact factor: 5.182

9.  Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation.

Authors:  T Shuto; G Sarkar; J T Bronk; N Matsui; M E Bolander
Journal:  J Bone Miner Res       Date:  1997-03       Impact factor: 6.741

10.  Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis.

Authors:  A Rebbapragada; H Benchabane; J L Wrana; A J Celeste; L Attisano
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

View more
  66 in total

1.  The relationship between bone mechanical properties and ground reaction forces in normal and hypermuscular mice.

Authors:  Daniel Schmitt; Ann C Zumwalt; Mark W Hamrick
Journal:  J Exp Zool A Ecol Genet Physiol       Date:  2010-07-01

Review 2.  Implications of exercise-induced adipo-myokines in bone metabolism.

Authors:  Giovanni Lombardi; Fabian Sanchis-Gomar; Silvia Perego; Veronica Sansoni; Giuseppe Banfi
Journal:  Endocrine       Date:  2015-12-30       Impact factor: 3.633

3.  Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury.

Authors:  Mark W Hamrick; Phonepasong Arounleut; Ethan Kellum; Matthew Cain; David Immel; Li-Fang Liang
Journal:  J Trauma       Date:  2010-09

4.  Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression.

Authors:  Moataz Elkasrawy; Sadanand Fulzele; Matthew Bowser; Karl Wenger; Mark Hamrick
Journal:  Growth Factors       Date:  2011-07-15       Impact factor: 2.511

Review 5.  Muscle-bone interactions: basic and clinical aspects.

Authors:  Luisella Cianferotti; Maria Luisa Brandi
Journal:  Endocrine       Date:  2013-08-29       Impact factor: 3.633

6.  Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.

Authors:  A K Oestreich; S M Carleton; X Yao; B A Gentry; C E Raw; M Brown; F M Pfeiffer; Y Wang; C L Phillips
Journal:  Osteoporos Int       Date:  2015-07-16       Impact factor: 4.507

7.  Inhibition of myostatin signal pathway may be involved in low-intensity pulsed ultrasound promoting bone healing.

Authors:  Lijun Sun; Shuxin Sun; Xinjuan Zhao; Jing Zhang; Jianzhong Guo; Liang Tang; Dean Ta
Journal:  J Med Ultrason (2001)       Date:  2019-08-03       Impact factor: 1.314

Review 8.  Effects of myokines on bone.

Authors:  Hiroshi Kaji
Journal:  Bonekey Rep       Date:  2016-07-20

9.  Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume.

Authors:  Ethan Kellum; Harlan Starr; Phonepasong Arounleut; David Immel; Sadanand Fulzele; Karl Wenger; Mark W Hamrick
Journal:  Bone       Date:  2008-09-13       Impact factor: 4.398

10.  HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy.

Authors:  Adam W Beharry; Pooja B Sandesara; Brandon M Roberts; Leonardo F Ferreira; Sarah M Senf; Andrew R Judge
Journal:  J Cell Sci       Date:  2014-01-24       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.